$SRRK

Invus reports 8.0% stake in Scholar Rock (SRRK) through 9.6M shares

Scholar Rock Holding Corp. disclosed an amended Schedule 13G showing Invus Public Equities, L.P. and affiliates beneficially own 9,575,013 shares, or 8.0% of Scholar Rock’s common stock, based on 119,828,338 shares outstanding as of May 4, 2026. The filing states the stake is passive and not intended to change or influence control.

Original reporting
Published Aug 13, 2026, 3:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 14, 2026, 6:56 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$SRRK
Neutral
medium confidence
Mentioned
$SRRK
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$SRRKNeutralLow
01

Why it matters

The new information is the reported beneficial ownership level (8.0%) and the group structure, which can affect how investors model potential governance influence even under a passive classification.

02

Market read

An 8.0% passive stake disclosure is a tangible ownership datapoint that can drive short-term positioning and sentiment, but it is not a stated control or activist catalyst.

03

What to watch

Traders may overestimate activism risk; the key incremental signal is stake size and sole voting/dispositive power, not a stated plan to change management.

Relevance 4/10Novelty 5/10Timing: today’s trading may react to fresh SEC 13G/A ownership disclosure

Background

The article summarizes an amended Schedule 13G/A for Scholar Rock, detailing Invus Public Equities and related entities’ beneficial ownership and control relationships.

Company-level read

Ticker impact

$SRRKNeutralMedium confidence
Context

Invus and affiliates filed an amended Schedule 13G reporting 9,575,013 shares, or 8.0%, of Scholar Rock common stock.

Expected impact

Near-term price impact is likely limited, but the disclosure may support modest sentiment and trading interest around ownership/float dynamics.

Evidence & confidence

The filing is a primary SEC ownership disclosure with a clear stake size (8.0%) and voting/dispositive power (sole), but it explicitly states the shares were not acquired to change or influence control, reducing catalyst strength.

Market effects

Limited sector read-through; this is company-specific ownership reporting rather than a sector-wide regulatory or clinical development.

No clear regional spillover beyond US small/mid-cap biotech ownership sentiment.

Minimal global relevance; the event is a US SEC filing tied to a single issuer.

Counterpoint

Because the filing is explicitly passive and control is not the intent, the market may treat it as routine and fade any initial reaction.

Key entities

  • Scholar Rock Holding Corporation

    The company whose common stock ownership stake is disclosed in the amended Schedule 13G/A.

  • Invus Public Equities, L.P.

    Lead reporting entity in the Schedule 13G/A that beneficially owns 9,575,013 shares (8.0%).

  • Raymond Debbane

    Named as a beneficial owner through control relationships within the reporting group.

Related articles

$RAREMed

Weekly Buzz: RARE, BAYRY Win Approvals; SION Cuts Jobs, GSK Deals; AZN, RHHBY Lead

Ultragenyx (RARE) gained FDA approval for FAYUVI, a treatment for Sanfilippo syndrome Type A, closing at $14.50, up 12.58%. Nuvation Bio (NUVB) expanded IBTROZI's label with new lung cancer data, closing at $6.07, up 5.02%. Bayer (BAYRY) won FDA approval for Kerendia in type 1 diabetes-related CKD, closing at $14.13, up 0.57%. Biogen (BIIB) and Eisai (ESALY.PK) received Japan approval for LEQEMBI Pen, closing at $219.05, up 1.41%. Telix (TLX) got FDA approval for Pixclara, a PET imaging agent fo

$SRRKMedAI 9/10

Scholar Rock Holding (SRRK) Wins FDA Approval for ISEMBYLD. Can Add-On Use Scale?

Scholar Rock Holding (SRRK) received FDA approval for ISEMBYLD, a treatment for spinal muscular atrophy in patients aged 2+. The drug showed a 2.2-point advantage over placebo in motor ability tests. The company is launching the product in the U.S., with support programs for insurance and infusions. Commercial success depends on patient access and treatment persistence, with safety concerns and reimbursement terms being key factors.

$SRRKMed

SRRK Maintained by Evercore ISI Group -- Price Target Raised to

Evercore ISI Group analyst Cory Kasimov maintained an 'Outperform' rating on Scholar Rock Holding Corp (SRRK) and raised the price target from $65.00 to $72.00, a 10.77% increase. SRRK's current price is $47.34 with a market cap of $5.77 billion. The company's GF Score™ is 29/100, indicating room for improvement in financial metrics. Insider activity shows $923,107 in sales over the last three months. The company focuses on biotechnology, developing therapies for rare neuromuscular diseases.

$SRRKHighAI 9/10

Scholar Rock wins FDA approval for spinal muscle atrophy drug

Scholar Rock received FDA approval for Isembyld, a drug targeting muscle loss in spinal muscular atrophy (SMA). The approval follows successful clinical trials showing improved motor skills in patients. The drug is approved for use with existing SMA therapies. Scholar Rock, valued at $6.8B, addressed manufacturing issues before resubmission. Pricing details are pending.